102 related articles for article (PubMed ID: 22251094)
1. Novel dihydroquinoline-based MABAs; clues to the identity of LAS-190792: evaluation of WO20111411802.
Norman P
Expert Opin Ther Pat; 2012 Feb; 22(2):185-92. PubMed ID: 22251094
[TBL] [Abstract][Full Text] [Related]
2. Multivalent dual pharmacology muscarinic antagonist and β₂ agonist (MABA) molecules for the treatment of COPD.
Hughes AD; McNamara A; Steinfeld T
Prog Med Chem; 2012; 51():71-95. PubMed ID: 22520472
[No Abstract] [Full Text] [Related]
3. Discovery of muscarinic acetylcholine receptor antagonist and beta 2 adrenoceptor agonist (MABA) dual pharmacology molecules.
Hughes AD; Chin KH; Dunham SL; Jasper JR; King KE; Lee TW; Mammen M; Martin J; Steinfeld T
Bioorg Med Chem Lett; 2011 Mar; 21(5):1354-8. PubMed ID: 21310610
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of WO-2012085582 and WO-2012085583 two identified MABAs: backups to AZD-2115?
Norman P
Expert Opin Ther Pat; 2012 Nov; 22(11):1377-83. PubMed ID: 22917191
[TBL] [Abstract][Full Text] [Related]
5. Efficient conversion of a nonselective norepinephrin reuptake inhibitor into a dual muscarinic antagonist-β₂-agonist for the treatment of chronic obstructive pulmonary disease.
Osborne R; Clarke N; Glossop P; Kenyon A; Liu H; Patel S; Summerhill S; Jones LH
J Med Chem; 2011 Oct; 54(19):6998-7002. PubMed ID: 21863888
[TBL] [Abstract][Full Text] [Related]
6. M(2)-β(2) interaction: a basis for combined bronchodilator treatment.
López-Campos JL
Arch Bronconeumol; 2013 Jul; 49(7):279-81. PubMed ID: 23122560
[No Abstract] [Full Text] [Related]
7. Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review.
Ray NC; Alcaraz L
Expert Opin Ther Pat; 2009 Jan; 19(1):1-12. PubMed ID: 19441894
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β
Rancati F; Linney ID; Rizzi A; Delcanale M; Knight CK; Schmidt W; Pastore F; Riccardi B; Mileo V; Carnini C; Cesari N; Blackaby WP; Patacchini R; Carzaniga L
Bioorg Med Chem Lett; 2021 Jun; 41():127975. PubMed ID: 33753262
[TBL] [Abstract][Full Text] [Related]
9. Molecular hybridization yields triazole bronchodilators for the treatment of COPD.
Jones LH; Burrows J; Feeder N; Glossop P; James K; Jones RM; Kenyon AS; Patel S; Roberts DF; Selby MD; Strang RS; Stuart EF; Trevethick MA; Watson J; Wright KN; Clarke N
Bioorg Med Chem Lett; 2015 Nov; 25(22):5121-6. PubMed ID: 26471092
[TBL] [Abstract][Full Text] [Related]
10. Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.
Hughes AD; Jones LH
Future Med Chem; 2011 Oct; 3(13):1585-605. PubMed ID: 21942250
[TBL] [Abstract][Full Text] [Related]
11. New bronchodilators.
Mak G; Hanania NA
Curr Opin Pharmacol; 2012 Jun; 12(3):238-45. PubMed ID: 22445544
[TBL] [Abstract][Full Text] [Related]
12. Inhalation by design: dual pharmacology β-2 agonists/M3 antagonists for the treatment of COPD.
Jones LH; Baldock H; Bunnage ME; Burrows J; Clarke N; Coghlan M; Entwistle D; Fairman D; Feeder N; Fulton C; Hilton L; James K; Jones RM; Kenyon AS; Marshall S; Newman SD; Osborne R; Patel S; Selby MD; Stuart EF; Trevethick MA; Wright KN; Price DA
Bioorg Med Chem Lett; 2011 May; 21(9):2759-63. PubMed ID: 21075627
[TBL] [Abstract][Full Text] [Related]
13. Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists.
Connolly S; Alcaraz L; Bailey A; Cadogan E; Christie J; Cook AR; Fisher AJ; Hill S; Humphries A; Ingall AH; Kane Z; Paine S; Pairaudeau G; Stocks MJ; Young A
Bioorg Med Chem Lett; 2011 Aug; 21(15):4612-6. PubMed ID: 21723724
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists.
Lainé DI; Xie H; Buffet N; Foley JJ; Buckley P; Webb EF; Widdowson KL; Palovich MR; Belmonte KE
Bioorg Med Chem Lett; 2007 Nov; 17(22):6066-9. PubMed ID: 17911022
[TBL] [Abstract][Full Text] [Related]
15. The discovery of AZD9164, a novel muscarinic M3 antagonist.
Mete A; Bowers K; Chevalier E; Donald DK; Edwards H; Escott KJ; Ford R; Grime K; Millichip I; Teobald B; Russell V
Bioorg Med Chem Lett; 2011 Dec; 21(24):7440-6. PubMed ID: 22047691
[TBL] [Abstract][Full Text] [Related]
16. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
Vogelmeier C; Banerji D
Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
[TBL] [Abstract][Full Text] [Related]
17. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists.
Marriott DP; Dougall IG; Meghani P; Liu YJ; Flower DR
J Med Chem; 1999 Aug; 42(17):3210-6. PubMed ID: 10464008
[TBL] [Abstract][Full Text] [Related]
18. Synthetic approaches to FDA approved drugs for asthma and COPD from 1969 to 2020.
Kazi AA; Subba Reddy BV; Ravithej Singh L
Bioorg Med Chem; 2021 Jul; 41():116212. PubMed ID: 34000507
[TBL] [Abstract][Full Text] [Related]
19. Alkyne-quinuclidine derivatives as potent and selective muscarinic antagonists for the treatment of COPD.
Starck JP; Provins L; Christophe B; Gillard M; Jadot S; Lo Brutto P; Quéré L; Talaga P; Guyaux M
Bioorg Med Chem Lett; 2008 Apr; 18(8):2675-8. PubMed ID: 18359633
[TBL] [Abstract][Full Text] [Related]
20. Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.
Shan WJ; Huang L; Zhou Q; Jiang HL; Luo ZH; Lai KF; Li XS
Bioorg Med Chem Lett; 2012 Feb; 22(4):1523-6. PubMed ID: 22297114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
